Research programme: sodium ion channel modulators - Purdue Pharma

Drug Profile

Research programme: sodium ion channel modulators - Purdue Pharma

Alternative Names: NaV1.7 ion channel modulators - Purdue Pharma

Latest Information Update: 03 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Purdue Pharma
  • Developer AnaBios Corporation; Purdue Pharma
  • Class Non-opioid analgesics
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Pain

Most Recent Events

  • 05 Dec 2016 Purdue license the rights to a suite of patents for NaV1.7 sodium ion channel blockers to AnaBios
  • 22 Sep 2015 Purdue Pharma and AnaBios form a joint venture to develop NaV1.7 sodium ion channel compounds for the treatment of chronic pain
  • 22 Sep 2015 Early research in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top